The use of checkpoint monotherapy in treating cancer has limited success. Post-translational modifications (PTM) of proteins such as glycosylation might have clinical implications due to distinct modifications found in diseases and its regulatory role in the immunometabolic gene expression. Such novel mechanistic targets hold great promise for combined immunotherapy.

See related article by Shi et al., p. 5990

©2020 American Association for Cancer Research.
2020
American Association for Cancer Research.
You do not currently have access to this content.